Regencell Bioscience (NASDAQ:RGC) Shares Gap Up – Should You Buy?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) gapped up prior to trading on Tuesday . The stock had previously closed at $22.09, but opened at $22.89. Regencell Bioscience shares last traded at $22.99, with a volume of 34,630 shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Monday, December 15th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Regencell Bioscience has an average rating of “Sell”.

Regencell Bioscience Price Performance

The company has a 50-day simple moving average of $15.09.

Hedge Funds Weigh In On Regencell Bioscience

Several hedge funds have recently modified their holdings of the stock. Greenfield Savings Bank acquired a new stake in Regencell Bioscience in the 2nd quarter worth approximately $187,000. Y Intercept Hong Kong Ltd acquired a new position in Regencell Bioscience during the 2nd quarter valued at approximately $222,000. XTX Topco Ltd purchased a new position in shares of Regencell Bioscience in the third quarter worth $598,000. BNP Paribas Financial Markets acquired a new stake in shares of Regencell Bioscience during the second quarter worth $768,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Regencell Bioscience during the second quarter valued at $1,701,000. Institutional investors and hedge funds own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.